



VIA HAND DELIVERY JANUARY 23, 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Lafleur et al.

Attorney Docket No.: PF482P1

Application Serial No.: 09/487,792

Art Unit: 1647

Filed: January 20, 2000

Examiner: Seharaseyon, J.

Title: Keratinocyte Derived Interferon

#16  
1/23/02  
RECEIVED  
JAN 28 2002  
TECH CENTER 1600/2900

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR 1.97**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AC-AI listed on the attached Form PTO/SB/08. Copies of references AC-AI are enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability

01/28/2002 MWOLDER1 00000255 083425 09487792

01 FC:126 180.00 CH

over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), because this Supplemental Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits, but before the mailing date of a final action under § 1.113, a notice of allowance, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Supplemental Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the fee required under 37 C.F.R. § 1.17(p). However, should the Patent Office determine otherwise, please charge any required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: January 23, 2002

  
Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (301) 315-2723

KKH/JMM/CCB/ba